Celcuity Inc.: Business Overview, Financials & Competitive Analysis

Celcuity Inc. Overview

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for treatment of various solid tumors. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent pan-PI3K and mTORC1/2 inhibitor. The CELsignia companion diagnostic platform analyzes live patient tumor cells to identify new groups of cancer patients, enabling precision oncology approaches.

Strategic Profile

In 2021, Celcuity licensed gedatolisib from Pfizer, giving it a late-stage therapeutic asset and moving it more directly into drug development. The company is advancing Phase 3 clinical trials with VIKTORIA-2, evaluating gedatolisib in combination with standard-of-care therapies for treatment-naive advanced breast cancer patients in both endocrine-resistant and endocrine-sensitive settings. Celcuity's competitive advantage lies in its proprietary diagnostics platform integrated with targeted drug development.

Competitive Landscape

Celcuity faces competition from other targeted therapies and antibody-drug conjugates, a moving standard of care in breast cancer, and manufacturing and regulatory complexity. The precision oncology and breast cancer treatment space includes established players leveraging companion diagnostics and combination strategies. Celcuity's differentiation rests on its dual PI3K/mTOR inhibitor mechanism and CELsignia platform-driven patient stratification.

Industry Context

Celcuity Inc. operates in Oncology Drugs.

Key facts

Founded: 2011 · Headquarters: Minneapolis, Minnesota, US · Employees: 155 · Revenue: Estimated $0-50M (pre-commercial/early commercial stage as of August 2026) · Market cap: $4.28B (as of August 2026)